• Eisai to sell anti-rheumatic injection in Japan biospectrumasia
    May 13, 2019
    Eisai Co., Ltd. has entered into a license agreement with medac Gesellschaft für klinische Spezialpräparate mbH (Medac) for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan.
PharmaSources Customer Service